glp-1 drugs insurance coverage What Is Prior Authorization for GLP-1s? The GLP-1 Access Gap: Mapping
Description
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jdar E, Leiter LA, et al
So far, the safety profile appears reassuring
One of the most consequential changes in 2026 is the loss of exclusivity for semaglutide, beginning in early 2026 across major markets including India, China, Brazil, Turkey and Canada, with semaglutide having lost exclusivity in India on 20th March 2026
in 2020 shed light on a critical connection: increased adiposity (body fat) significantly raises the risk of developing RA
A study that would be very challenging to run (controlled fixed diet - with and without GLP1)
